Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Blood. 2013 Nov 14;122(20):3398-400. doi: 10.1182/blood-2013-09-526392.

Asparaginase unveils glutamine-addicted AML.

Author information

  • 1TERRY FOX LABORATORY;

Abstract

In this issue of Blood, Willems et al describe the dependence of acute myeloid leukemia (AML) cells on glutamine for maintaining protein synthesis downstream of mammalian target of rapamycin (mTOR) and show that the enzyme asparaginase can be used to target this dependence. Using various AML cell lines, primary samples, and CD341 stem cells from healthy donors, the authors support the notion that asparaginase may offer a therapeutic benefit in AML—not from its well-known enzymatic activity, but from its “off-target” effects on glutamine levels that result in inhibition of downstream mTOR signaling, inhibition of protein synthesis, and ultimately loss of viability.

Comment on

PMID:
24235130
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk